These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33684402)

  • 1. Diagnostic accuracy comparison of three fully automated chemiluminescent immunoassay platforms for the detection of SARS-CoV-2 antibodies.
    Parai D; Dash GC; Choudhary HR; Peter A; Rout UK; Nanda RR; Kshatri JS; Kanungo S; Pati S; Bhattacharya D
    J Virol Methods; 2021 Jun; 292():114121. PubMed ID: 33684402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.
    Infantino M; Grossi V; Lari B; Bambi R; Perri A; Manneschi M; Terenzi G; Liotti I; Ciotta G; Taddei C; Benucci M; Casprini P; Veneziani F; Fabbri S; Pompetti A; Manfredi M
    J Med Virol; 2020 Sep; 92(9):1671-1675. PubMed ID: 32330291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays.
    Harley K; Gunsolus IL
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33106364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19.
    Chiereghin A; Zagari RM; Galli S; Moroni A; Gabrielli L; Venturoli S; Bon I; Rossini G; Saracino IM; Pavoni M; Lafratta S; Deni A; Felici S; Borghi M; Guerra L; Raumer L; Lodi V; Viale P; Attard L; Lazzarotto T;
    Front Public Health; 2020; 8():620222. PubMed ID: 33681115
    [No Abstract]   [Full Text] [Related]  

  • 5. Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain.
    Poljak M; Oštrbenk Valenčak A; Štamol T; Seme K
    J Clin Virol; 2021 Apr; 137():104784. PubMed ID: 33711693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course.
    Higgins V; Fabros A; Wang XY; Bhandari M; Daghfal DJ; Kulasingam V
    Clin Biochem; 2021 Apr; 90():1-7. PubMed ID: 33476578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay.
    Kittel M; Findeisen P; Muth MC; Thiaucourt M; Gerhards C; Neumaier M; Haselmann V
    Int J Infect Dis; 2021 Apr; 105():632-638. PubMed ID: 33578017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies.
    Weber MC; Risch M; Thiel SL; Grossmann K; Nigg S; Wohlwend N; Lung T; Hillmann D; Ritzler M; Ferrara F; Bigler S; Egli K; Bodmer T; Imperiali M; Salimi Y; Fleisch F; Cusini A; Heer S; Renz H; Paprotny M; Kohler P; Vernazza P; Risch L; Kahlert CR
    Dis Markers; 2021; 2021():8810196. PubMed ID: 33532006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance of the Advia Centaur anti-SARS-CoV-2 chemiluminescent immunoassay related to antibody kinetics.
    Ocmant A; Roisin S; De Meuter R; Brauner J
    J Med Virol; 2021 May; 93(5):2583-2584. PubMed ID: 33448403
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients.
    Soleimani R; Khourssaji M; Gruson D; Rodriguez-Villalobos H; Berghmans M; Belkhir L; Yombi JC; Kabamba-Mukadi B
    J Med Virol; 2021 Mar; 93(3):1465-1477. PubMed ID: 32797641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of commercial automated SARS-CoV-2 immunoassays.
    Kittel M; Muth MC; Zahn I; Roth HJ; Thiaucourt M; Gerhards C; Haselmann V; Neumaier M; Findeisen P
    Int J Infect Dis; 2021 Feb; 103():590-596. PubMed ID: 33310108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of three automatic chemiluminescent immunoassays for monitoring dynamic profile of SARS-CoV-2 IgG and IgM.
    Dou X; Wang E; Hu J; Zong Z; Jiang R; Wang M; Kan L; Zhang X
    J Clin Lab Anal; 2021 Jan; 35(1):e23681. PubMed ID: 33340166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management.
    Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C
    Front Immunol; 2020; 11():609242. PubMed ID: 33424863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies.
    Hubbard JA; Geno KA; Khan J; Szczepiorkowski ZM; de Gijsel D; Ovalle AA; AlSalman AS; Gallagher TL; Johnston AA; Tibbetts AR; Vital SE; Cervinski MA; Nerenz RD
    J Appl Lab Med; 2021 Mar; 6(2):429-440. PubMed ID: 32976593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and performance comparison of three SARS-CoV-2 antibody assays.
    Paiva KJ; Grisson RD; Chan PA; Huard RC; Caliendo AM; Lonks JR; King E; Tang EW; Pytel-Parenteau DL; Nam GH; Yakirevich E; Lu S
    J Med Virol; 2021 Feb; 93(2):916-923. PubMed ID: 32710669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott).
    Charpentier C; Ichou H; Damond F; Bouvet E; Chaix ML; Ferré V; Delaugerre C; Mahjoub N; Larrouy L; Le Hingrat Q; Visseaux B; Mackiewicz V; Descamps D; Fidouh-Houhou N
    J Clin Virol; 2020 Nov; 132():104618. PubMed ID: 32919222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).
    Nicol T; Lefeuvre C; Serri O; Pivert A; Joubaud F; Dubée V; Kouatchet A; Ducancelle A; Lunel-Fabiani F; Le Guillou-Guillemette H
    J Clin Virol; 2020 Aug; 129():104511. PubMed ID: 32593133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.